```html

Killer Cell Immunodeficiency Syndrome (Hemophagocytic Lymphohistiocytosis)

Overview

Hemophagocytic lymphohistiocytosis (HLH), also called Killer cell immunodeficiency syndrome, is a rare, life‑threatening disorder of the immune system. In HLH, highly activated cytotoxic T‑cells and natural‑killer (NK) cells release an excess of inflammatory cytokines, leading to uncontrolled activation of macrophages that “eat” (phagocytose) blood cells in the bone marrow, spleen, liver, and other organs.

The disease can be primary (familial), caused by inherited genetic mutations that impair the killing function of NK and CD8⁺ T‑cells, or secondary (acquired), triggered by infections, malignancies, or autoimmune conditions.

• Incidence: Estimated 1–2 cases per million children per year for the familial form; the acquired form is less well‑quantified but likely under‑diagnosed.
• Age distribution: Primary HLH typically presents in infants and young children (<2 years), while secondary HLH can affect adolescents and adults.
• Sex: No consistent male‑to‑female predominance.

Sources: NIH National Institute of Allergy and Infectious Diseases; Mayo Clinic; WHO (2023).

Symptoms

Symptoms develop rapidly—often within days to weeks—and reflect widespread inflammation and organ infiltration. The classic “5‑point” clinical criteria (fever, splenomegaly, cytopenias, hypertriglyceridemia/fibrinogenemia, hemophagocytosis) are supplemented by many other findings.

Core symptoms

• Fever: Persistent, high‑grade (≥38.5 °C) often unresponsive to antipyretics.
• Splenomegaly: Enlarged spleen causing left‑upper‑quadrant fullness or pain.
• Cytopenias: At least two of three lineages low (hemoglobin <9 g/dL, neutrophils <1,000/µL, platelets <100,000/µL).
• Hypertriglyceridemia & hypofibrinogenemia: Fasting triglycerides ≥265 mg/dL or fibrinogen ≤150 mg/dL.
• Hemophagocytosis: Macrophages engulfing blood cells on bone‑marrow, liver, or lymph‑node biopsy.

Additional common findings

• Elevated serum ferritin (>500 ng/mL; often >10,000 ng/mL in severe cases).
• High soluble IL‑2 receptor (sCD25) levels.
• Liver involvement: hepatitis, jaundice, abdominal pain.
• Neurologic signs: irritability, seizures, ataxia, or altered mental status due to CNS infiltration.
• Coagulopathy: prolonged PT/aPTT, bleeding or bruising.
• Skin rash or erythema.
• Respiratory distress from pulmonary infiltrates or effusions.

Causes and Risk Factors

HLH can be divided into genetic (primary) and acquired (secondary) categories.

Primary (Familial) HLH

• Mutations in genes critical for cytolytic granule exocytosis: PRF1 (perforin), UNC13D (Munc13‑4), STX11, STXBP2, among others.
• Inherited in an autosomal‑recessive pattern (except rare X‑linked SH2D1A causing X‑linked lymphoproliferative disease).
• Family history of early childhood deaths from unexplained fever or infections raises suspicion.

Secondary (Acquired) HLH

• Infections: Epstein‑Barr virus (EBV), cytomegalovirus, HIV, hepatitis viruses, bacterial sepsis, or fungal infections.
• Malignancies: T‑cell or NK‑cell lymphomas, leukemias, or solid tumors.
• Autoimmune/rheumatic disorders: Systemic lupus erythematosus, adult‑onset Still’s disease, juvenile rheumatoid arthritis (macrophage activation syndrome).
• Immunosuppression: Post‑transplant patients, patients on biologic agents (e.g., CAR‑T therapy).
• Genetic predisposition: Heterozygous carrier status for HLH‑related genes may increase susceptibility when combined with a trigger.

Who Is at Higher Risk?

• Infants with a sibling who died of “unexplained fever” or “sepsis.”
• Individuals of Asian or Middle‑Eastern descent have slightly higher rates of certain familial mutations (e.g., PRF1).
• Patients with known EBV infection or lymphoproliferative disorders.
• Adults receiving chimeric antigen receptor (CAR) T‑cell therapy, which can precipitate cytokine release syndrome resembling HLH.

Diagnosis

Because HLH mimics severe infection or sepsis, a high index of suspicion is essential. The International Histiocyte Society establishes diagnostic criteria; meeting 5 of 8 clinical/laboratory findings confirms HLH.

International HLH‑2004 Diagnostic Criteria

1. Fever
2. Splenomegaly
3. Cytopenia affecting ≥2 lineages
4. Hypertriglyceridemia (≥265 mg/dL) and/or hypofibrinogenemia (≤150 mg/dL)
5. Hemophagocytosis in bone‑marrow, spleen, or lymph node
6. Low or absent NK‑cell activity
7. Ferritin ≥500 ng/mL (often >10,000 ng/mL)
8. Elevated soluble CD25 (sIL‑2 receptor) ≥2400 U/mL

Key Diagnostic Tests

• Complete blood count (CBC) with differential: Detects anemia, neutropenia, thrombocytopenia.
• Liver function panel & coagulation studies: AST/ALT, bilirubin, PT/PTT.
• Lipid profile: Fasting triglycerides.
• Serum ferritin and triglycerides.
• Soluble CD25 (sIL‑2R) assay: Marker of T‑cell activation.
• NK‑cell cytotoxicity assay: Flow‑cytometry based test; low activity supports diagnosis.
• Bone‑marrow aspiration/biopsy: Demonstrates hemophagocytosis; also rules out malignancy.
• Genetic testing: Targeted panels or whole‑exome sequencing for HLH‑associated genes (especially in children).
• Infectious work‑up: EBV PCR, CMV PCR, HIV test, bacterial cultures, viral panels.
• Neuroimaging (MRI) & CSF analysis: If neurologic symptoms are present.

Rapid Assessment Tools

The HScore (developed by the French HLH Study Group) integrates clinical and laboratory variables to estimate the probability of HLH in adults. A score ≥ 169 correlates with a >80 % chance of disease.

Treatment Options

Prompt therapy is crucial—delayed treatment increases mortality to >50 % in severe cases. Therapy is aimed at (1) suppressing hyperinflammation, (2) treating the trigger, and (3) restoring immune regulation.

Initial Stabilization

• Intensive care unit (ICU) monitoring for hemodynamic instability.
• Broad‑spectrum antibiotics until infection is ruled out.
• Transfusion support for anemia or coagulopathy.
• Fluid and electrolyte management; avoid volume overload.

Immunosuppressive & Cytotoxic Regimens

Most centers follow the HLH‑94 or HLH‑2004 protocols:

• Etoposide (VP‑16): 150 mg/m² IV twice weekly for the first 2 weeks, then weekly. It induces apoptosis of activated T‑cells and macrophages.
• Dexamethasone: High‑dose (10 mg/m²/day) with a taper over 8 weeks; penetrates the CNS.
• Cyclosporine A: Added after week 2 (after etoposide) for continued T‑cell inhibition.

Treatment of Underlying Triggers

• Antiviral therapy (e.g., ganciclovir for CMV, rituximab for EBV‑driven HLH).
• Chemotherapy or targeted agents for lymphoma‑associated HLH.
• Immunomodulators (e.g., anakinra, tocilizumab) for cytokine storm secondary to autoimmune disease.

Biologic & Targeted Options (Emerging)

• Emapalumab: Anti‑IFN‑γ monoclonal antibody approved by FDA (2021) for refractory primary HLH.
• Ruxolitinib: JAK1/2 inhibitor—reduces cytokine signaling; used in both primary and secondary HLH.
• Novantrone (mitoxantrone) & other alkylators: Reserve for salvage therapy.

Hematopoietic Stem Cell Transplant (HSCT)

Curative for familial HLH and many refractory cases. Ideally performed after disease control with the above regimen. Donor selection (matched sibling, unrelated, or haploidentical) and conditioning intensity are individualized.

Lifestyle & Supportive Measures

• Nutrition: High‑calorie, high‑protein diet; consider enteral feeding if oral intake poor.
• Infection prophylaxis: Trimethoprim‑sulfamethoxazole, antifungal agents, and antivirals as indicated.
• Psychosocial support: Counseling for patient and family; connect with HLH support groups.

Living with Killer Cell Immunodeficiency Syndrome (Hemophagocytic Lymphohistiocytosis)

Even after remission, survivors face ongoing challenges.

Long‑Term Monitoring

• Regular CBC, ferritin, triglycerides, and liver function tests every 1–3 months for the first year, then semi‑annually.
• Annual neuro‑cognitive assessment if CNS involvement was present.
• Serial EBV or other viral PCRs in patients with known viral triggers.
• Post‑HSCT surveillance for graft‑versus‑host disease, infections, and organ toxicity.

Daily Management Tips

• Medication adherence: Keep a pill organizer; set alarms for immunosuppressants.
• Vaccinations: Inactivated vaccines are safe; live vaccines should be avoided unless immunity is documented.
• Infection avoidance: Hand hygiene, avoid crowded places during outbreaks, wear masks if immunocompromised.
• Energy conservation: Pace activities; schedule rest periods to combat fatigue.
• Nutrition: Small, frequent meals; supplement with vitamins D and B12 if deficient.
• Psychological health: Join HLH patient forums; consider therapy for anxiety or depression.

When to Contact Your Healthcare Team

• New fever, chills, or worsening fatigue.
• Unexplained bruising, bleeding, or dark stools.
• Rapid weight loss or swelling of the abdomen.
• Neurologic changes such as headache, confusion, or seizures.

Prevention

Because HLH can be triggered by infections or malignancy, prevention focuses on reducing these risks and, for families with known genetic mutations, early identification.

• Genetic counseling and carrier testing for relatives of patients with primary HLH.
• Prompt treatment of viral infections (especially EBV) in at‑risk children.
• Adherence to cancer screening guidelines; early detection of lymphomas.
• Vaccination according to CDC schedules (non‑live vaccines) to lower infection burden.
• Strict infection‑control practices for immunosuppressed patients (hand hygiene, mask use).

Complications

If untreated or inadequately controlled, HLH can lead to severe, often irreversible damage.

• Multi‑organ failure: Liver failure, acute respiratory distress syndrome (ARDS), renal failure.
• Severe cytopenias: Life‑threatening anemia, bleeding, or infections due to neutropenia.
• Neurologic sequelae: Cognitive impairment, seizures, permanent motor deficits.
• Coagulopathy & DIC: Disseminated intravascular coagulation leading to hemorrhage.
• Secondary malignancies: Particularly after prolonged immunosuppression or HSCT.
• Relapse: Approximately 30 % of patients experience recurrence, especially without HSCT.

Sources: Cleveland Clinic; J. Clin. Immunol. 2022; CDC HLH guidelines 2021.

When to Seek Emergency Care

References: Mayo Clinic; NIH National Library of Medicine; WHO; JAMA Immunology 2023; American Academy of Pediatrics HLH guidelines.

```